Advances in translational research provide a rationale for clinical re-evaluation of high-dose radiotherapy for glioblastoma

Medical Hypotheses

Volumn 76, Issue 3, 2011, Pages 410-413

  Nieder, Carsten ^a,b   Mehta, Minesh P ^c  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR; MARKER; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL KILLING; CELL SUBPOPULATION; CLINICAL EVALUATION; CYTOREDUCTIVE SURGERY; DNA REPAIR; GLIOBLASTOMA; HUMAN; MULTIPLE CYCLE TREATMENT; OXYGENATION; RADIATION DOSE; RADIOSENSITIVITY; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; VASCULARIZATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; DACARBAZINE; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; GLIOBLASTOMA; HUMANS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; TRANSLATIONAL RESEARCH;

EID: 79751534681     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2010.11.005     Document Type: Article

References (42)

1. Wen P.Y., Kesari S. Malignant gliomas in adults. N Engl J Med 2008, 359:492-507.
2. Nieder C., Mehta M.P., Jalali R. Combined radio- and chemotherapy of brain tumours in adult patients. Clin Oncol (R Coll Radiol) 2009, 21:515-524.
3. Kristiansen K., Hagen S., Kollevold T., et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981, 47:649-652.
4. Walker M.D., Alexander E., Hunt W.E., et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. J Neurosurg 1978, 49:333-343.
5. Nieder C., Andratschke N., Wiedenmann N., Busch R., Grosu A.L., Molls M. Radiotherapy for high-grade gliomas: does altered fractionation improve the outcome?. Strahlenther Onkol 2004, 180:401-407.
6. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
7. Wallner K.E., Galicich J.H., Krol G., Arbit E., Malkin M.G. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989, 16:1405-1409.
8. Hochberg F.H., Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980, 30:907-911.
9. Suit H.D., Zietman A., Tomkinson K., Ramsay J., Gerweck L., Sedlacek R. Radiation response of xenografts of a human squamous cell carcinoma and a glioblastoma multiforme: a progress report. Int J Radiat Oncol Biol Phys 1990, 18:365-373.
10. Walker M.D., Strike T.S., Sheline G.E. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979, 5:1725-1731.
11. Bleehen N.M., Stenning S.P. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Br J Cancer 1991, 64:769-774.
12. Larson D.A., Gutin P.H., Leibel S.A., Phillips T.L., Sneed P.K., Wara W.M. Stereotaxic irradiation of brain tumors. Cancer 1990, 65:792-799.
13. Loeffler J.S., Alexander E., Wen P.Y., et al. Results of stereotactic brachytherapy used in the initial management of patients with glioblastoma. J Natl Cancer Inst 1990, 82:1918-1921.
14. Fitzek M.M., Thornton A.F., Rabinov J.D., et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: results of a phase II prospective trial. J Neurosurg 1999, 91:251-260.
15. Gutin P.H., Prados M.D., Phillips T.L., et al. External irradiation followed by an interstitial high activity iodine-125 implant "boost" in the initial treatment of malignant gliomas: NCOG study 6G-82-2. Int J Radiat Oncol Biol Phys 1991, 21:601-606.
16. Souhami L., Seiferheld W., Brachman D., et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. Int J Radiat Oncol Biol Phys 2004, 60:853-860.
17. Choe G., Horvath S., Cloughesy T.F., et al. Analysis of the phosphatidylinositol 3'-kinase signalling pathway in glioblastoma patients in vivo. Cancer Res 2003, 63:2742-2746.
18. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
19. Hegi M.E., Liu L., Herman J.G., et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008, 26:4189-4199.
20. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
21. Liu Y., Shete S., Etzel C.J., et al. Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. J Clin Oncol 2010, 28:2467-2474.
22. Chaudhry MA, Sachdeva H, Omaruddin RA. Radiation-induced micro-RNA modulation in glioblastoma cells differing in DNA-repair pathways. DNA Cell Biol 2010 [Epub ahead of print].
23. Mukherjee B., McEllin B., Camacho C.V., et al. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 2009, 69:4252-4259.
24. Chakravarti A., Chakladar A., Delaney M.A., et al. The epidermal receptor growth factor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 2002, 62:4307-4315.
25. Eshleman J.S., Carlson B.L., Mladek A.C., et al. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 2002, 62:7291-7297.
26. Lammering G., Hewit T.H., Valerie K., et al. Anti-erbB receptor strategy as a gene therapeutic intervention to improve radiotherapy in malignant human tumours. Int J Radiat Biol 2003, 79:561-568.
27. Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
28. Grosu A.L., Weber W.A., Riedel E., et al. L-(methyl-11C) methionine positron emission tomography for target delineation in resected high-grade gliomas before radiotherapy. Int J Radiat Oncol Biol Phys 2005, 63:64-74.
29. Rickhey M., Koelbl O., Eilles C., Bogner L. A biologically adapted dose-escalation approach, demonstrated for 18F-FET-PET in brain tumors. Strahlenther Onkol 2008, 184:536-542.
30. Grosu A.L., Weber W.A., Franz M., et al. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys 2005, 63:511-519.
31. Weber D.C., Zilli T., Buchegger F., et al. [(18)F]Fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma. Radiat Oncol 2008, 3:44.
32. Ullrich R.T., Kracht L.W., Jacobs A.H. Neuroimaging in patients with gliomas. Semin Neurol 2008, 28:484-494.
33. Hamstra D.A., Galbán C.J., Meyer C.R., et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival. J Clin Oncol 2008, 26:3387-3394.
34. Grosu A.L., Nestle U., Weber W.A. How to use functional imaging information for radiotherapy planning. Eur J Cancer 2009, 45(Suppl. 1):461-463.
35. Fine H.A., Dear K.B., Loeffler J.S., et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993, 71:2585-2597.
36. Stewart L.A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359:1011-1018.
37. Van Rijn J., Heimans J.J., van den Berg J., van der Valk P., Slotman B.J. Survival of human glioma cells treated with various combinations of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 2000, 47:779-784.
38. Kil W.J., Cerna D., Burgan W.E., et al. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 2008, 14:931-938.
39. Carlson B.L., Grogan P.T., Mladek A.C., et al. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int J Radiat Oncol Biol Phys 2009, 75:212-219.
40. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
41. Brandes A.A., Franceschi E., Tosoni A., et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008, 26:2192-2197.
42. Kioi M., Vogel H., Schultz G., Hoffman R.M., Harsh G.R., Brown J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010, 120:694-705.